Heart age estimated using explainable advanced electrocardiography 1 Thomas Lindow, MD, PhD^{1,2,3*}, Israel Palencia-Lamela, 1,4* Todd T Schlegel, MD^{5,6}, 2 Martin Ugander, MD, PhD^{1,5} 3 1. Kolling Institute, Royal North Shore Hospital, and University of Sydney, Sydney, Australia 4 2. Department of Clinical Physiology, Research and Development, Växjö Central Hospital, 5 Region Kronoberg, Sweden 6 3. Clinical Physiology, Clinical Sciences, Lund University, Sweden 4. Davidson College, Davidson, North Carolina, USA 9 5. Department of Clinical Physiology, Karolinska Institutet, and Karolinska University 10 Hospital, Stockholm, Sweden 11 6. Nicollier-Schlegel SARL, Trélex, Switzerland 12 13 *Shared first-authorship by equal contribution 14 15 **Fundings:** TL is currently under the support of postdoctoral research grants from The 16 Swedish Heart-Lung Foundation (grant no 20200553), the Swedish Cardiac Society, the 17 Royal Swedish Academy of Sciences (grant no LM2019-0013), Women and Health 18 Foundation, Region Kronoberg (grant no 8301), The Swedish Heart and Lung Association (grant no LKH1387), Swedish Association of Clinical Physiology, and the Scandinavian 19 20 Society of Clinical Physiology&Nuclear Medicine. The study was funded in part by grants (PI Ugander) from New South Wales Health, Heart Research Australia, and the University of 21 22 Sydney. 23 **Author contributions:** TL and IPL contributed to study design, performed the data analysis, 24 wrote the first manuscript drafts, prepared the figures, and are shared first authors by equal 25 contributions. TTS curated the data, contributed to study design, performed the prediction 26 modeling, and critically revised the manuscript. MU designed the study, provided supervision, 27 and critically revised the manuscript. All authors read and approved the final version of the manuscript. 28 29 **Competing interests:** 30 TL, IPL: None TTS is owner and founder of Nicollier-Schlegel SARL, which performs ECG interpretation 31 32 consultancy using software that can quantify the advanced ECG measures used in the current 33 study. TTS and MU are owners and founders of Advanced ECG Systems, a company that is 34 developing commercial applications of advanced ECG technology used in the current study. 35 Corresponding author: Martin Ugander, martin.ugander@ki.se, Professor of Cardiac 36 37 Imaging, University of Sydney, Sydney, Australia, and Karolinska Institute, Sweden. 38

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

Background: Electrocardiographic (ECG) Heart Age conveying cardiovascular risk has been estimated by both Bayesian and artificial intelligence approaches. We hypothesised that explainable measures from the 10-second 12-lead ECG could successfully predict Bayesian 5min ECG Heart Age. **Methods:** Advanced analysis was performed on ECGs from healthy subjects and patients with cardiovascular risk or proven heart disease. Regression models were used to predict patients' Bayesian 5-minute ECG Heart Ages from their standard, resting 10-second 12-lead ECGs. The difference between 5-min and 10-second ECG Heart Ages were analyzed, as were the differences between 10-second ECG Heart Age and the chronological age (the Heart Age Gap). **Results**: In total, 2,771 subjects were included (n=1682 healthy volunteers, n=305 with cardiovascular risk factors, n=784 with cardiovascular disease). Overall, 10-second Heart Age showed strong agreement with the 5-minute Heart Age (R²=0.94, p<0.001, mean±SD bias 0.0±5.1 years). The Heart Age Gap was 0.0±5.7 years in healthy individuals, 7.4±7.3 years in subjects with cardiovascular risk factors (p<0.001), and 14.3±9.2 years in patients with cardiovascular disease (p<0.001). Conclusions: Heart Age can be accurately estimated from a 10-second 12-lead ECG in a transparent and explainable fashion based on known ECG measures, without artificial intelligence techniques. The Heart Age Gap increases markedly with cardiovascular risk and disease. **Keywords**: vascular age; electrocardiography cardiovascular risk prediction; advanced electrocardiography; vectorcardiography

Background

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

Cardiovascular disease is a significant contributor to mortality, with related pathological processes often beginning early and progressing silently for many years¹⁻³. Many risk factors for developing cardiovascular disease are lifestyle-related⁴. Fortunately, several are modifiable, and risk can therefore be reduced, for example by smoking cessation, dietary changes and increased physical activity^{5,6}. To accomplish this, an individual must fully understand their risk and become motivated to reduce it. One way of communicating risk to the patient is to present it as a "Heart Age", which can be contrasted to the patient's chronological age, i.e. a "Heart Age Gap". A Heart Age can either be determined by translating risk factor scores to what age a resultant score would represent in an individual with no risk factors, or it can be based on electrocardiographic changes⁷⁻¹². Describing the risk to the patient using Heart Age has been reported to reduce metabolic risk factors and may have the advantage of being easily understood by the patient^{11,13}. A similar approach has been applied when conveying risk to smokers by describing how 'old' their lungs are, and such an approach increased the chance of smoking cessation¹⁴. Moving beyond but not excluding basic ECG measurements such as heart rate and waveform amplitudes and durations, the diagnostic output from the ECG can be further substantially improved by also utilizing combinations of advanced ECG measures, for example those from 12-lead-ECG-derived vectorcardiography, waveform complexity, and measures of beat-tobeat waveform variablility 15-17. In 2014, such advanced measures were used along with 5minute, high-fidelity 12-lead ECGs and a Bayesian statistical approach, to develop an accurate estimate of ECG-based Heart Age. The estimation of Heart Age using this method has been described in detail elsewhere⁹. In brief, the Bayesian approach was used to infer the deviation of the Heart Age from the subject's known chronological age by assessing and quantifying an individual's expected versus actual ECG findings. In addition to sex and

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

chronological age itself, the ECG parameters used in the method as modifiers of the Bayesianpredicted Heart Age were the T-wave axis in the frontal plane, P-wave duration, frontal plane vectorcardiographic QRS axis, spatial JT interval, spatial mean QRS-T angle, high-frequency QRS root mean squared voltages across signal-averaged leads after band-pass filtering, beatto-beat QT- and RR-interval variability, and measures of T-wave complexity based on singular value decomposition and signal averaging of the T wave. After being trained on a set of healthy individuals, this approach was clinically validated by describing an increased difference between Heart Age and chronological age both for subjects at risk of cardiovascular disease, and those with established cardiovascular disease⁹. However, importantly, reliable measurement of beat-to-beat RR and QT interval variability requires ECG recordings of at least several minutes. In addition, accurate quantification of high frequency QRS root mean squared voltages requires higher-fidelity recordings with more specialised equipment and sampling rates exceeding the 250-500 samples per second used today in most ECG machines used for standard, 10-second ECG recordings. Therefore, the main aim of this study was to ascertain whether 5-minute ECG Heart Age could be accurately predicted by only those measures available from a standard 10-second 12-lead ECGs. Furthermore, a subsequent secondary aim was to also compare 10-second ECG Heart Ages to chronological ages in healthy subjects, subjects with cardiovascular risk factors, and patients with established cardiovascular disease. We hypothesised that standard-fidelity, 10-second 12-lead ECG recordings could accurately predict Bayesian ECG Heart Ages derived from higher-fidelity, 5-minute 12-lead ECG recordings. Methods A pre-existing database of de-identified subjects with both 5-minute and 10-second 12-lead ECG recordings was utilised for the study^{9,16}. Within that database, healthy individuals,

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

patients at cardiovascular risk, and patients with established cardiovascular disease were included. The healthy subjects, who had volunteered as asymptomatic controls, were recruited at Johnson Space Center (USA), the Universidad de los Andes (Venezuela), the University of Ljubljana hospitals and clinics (Slovenia), or Lund University Hospital (Sweden), as previously described in detail 16. Patients with cardiovascular risk factors or established cardiovascular disease were recruited from cardiology clinics at either Texas Heart Institute (Houston, USA); the University of Texas Medical Branch (Galveston, USA), the University of Texas Health Sciences Center (San Antonio, USA), Brooke Army Medical Center (San Antonio, USA); St. Francis Hospital (Charleston, USA), the Universidad de los Andes (Mérida, Venezuela); and Lund University Hospital (Lund, Sweden). All healthy subjects were low risk, asymptomatic volunteers with absence of any cardiovascular or systemic disease, based on clinical history and physical examination. Exclusion criteria for the healthy subjects included increased blood pressure at physical examination (≥140/90 mm Hg), treatment for hypertension or diabetes, or active smoking. Patients in the established cardiovascular disease group were included based on the presence of either coronary heart disease (determined by coronary angiography with at least one obstructed vessel (≥50%) in at least one major native coronary vessel or coronary graft, or, if coronary angiography was either unavailable or clinically not indicated, one or more reversible perfusion defects on 99m-Tc-tetrofosmin single-photon emission computed tomography (SPECT)¹⁸⁻²⁰), left ventricular hypertrophy (LVH) based on imaging evidence of at least moderate, concentric wall thickening according to guidelines of the American Society of Echocardiography²¹, left ventricular systolic dysfunction (left ventricular ejection fraction ≤50%) at echocardiography, cardiac magnetic resonance imaging (CMR) or SPECT, or findings suggestive of dilated/hypertrophic/ischemic cardiomyopathy at echocardiography or

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

CMR¹⁶. ECGs were acquired within 30 days of the cardiac imaging examination. Finally, subjects in the cardiovascular risk group were included based on the presence of cardiovascular risk factors such as hypertension or diabetes but no confirmed, established cardiovascular disease⁹. Based on the above, three groups of study participants were identified: healthy subjects, subjects at cardiovascular risk, and patients with established cardiovascular disease. By methodological design, only healthy subjects were initially included when considering optimal measures of 12-lead ECG available from 10-second recordings for predicting the 5minute ECG Heart Age. The 10-secondECG measures considered for the prediction model included: (1) From the conventional ECG: heart rate, R-to-R, P-wave, PR, QRS, QT, QTc, and TQ interval durations, as well as the conventional ECG amplitudes and axes; (2) From the transformation of the 12-lead ECG to the Frank X, Y and Z lead vectorcardiogram (VCG) via Kors' transform²²⁻²⁶: the spatial means and peaks QRS-T angles, the spatial ventricular gradient and its individual QRS and T components, the spatial QRS- and T-wave axes(azimuths and elevations), waveform amplitudes and areas, including those in the three individual vectorcardiographic planes, and spatial QRS-and T-wave velocities; and(3) Multiple measures of QRS-and T-wave waveform complexity based on singular value decomposition after signal averaging²⁷⁻²⁹. For all study participants, the Heart Age Gap was calculated as the 10-second ECG Heart Age minus chronological age. All results were compared between the three groups, and for subgroups based on sex and age (above or below 60 years). Each participant gave written informed consent. All recordings were obtained under Institutional Review Board (IRB) approvals from NASA's Johnson Space Center and partner

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

hospitals that fall under IRB exemptions for previously collected and de-identified data. The study was performed in accordance with the Declaration of Helsinki. Statistical analysis Continuous variables were described using mean and standard deviation (SD). The chisquared test was used to test for proportional differences between groups. Student's t test was used to compare group means. The 10-second ECG Heart Age was initially derived only in the healthy subject group. First, standard least squares linear regression was used to identify the most promising univariable measures available from 10-second, standard-fidelity ECG for predicting the 5-minute ECG Heart Age. More than 20 such measures were identified, along with chronological age and sex, that had individual P<0.0001. After the univariable linear regression identification procedure, stepwise, standard least squares multiple linear regression was then performed only on the selected measures to best predict, via multivariable model, the 5-minute ECG Heart Age in the healthy subject group. The optimal multivariable model was defined as the most parsimonious one that maintained the highest possible R-squared value while at the same time maintaining all p<0.0001 for the individual measures within the model in the healthy subject group, and at <0.01 when the model was subsequently applied forward to the non-healthy (cardiovascular risk and disease) groups. Comparisons with 5-minuteECG Heart Age are presented as scatter plots and Bland-Altman plots. A two-sided p-value of 0.05 was used as to define statistical significance. Statistical analyses were performed using SAS JMP version 11.0, SAS Institute Inc, Cary, NC, USA, and R version 3.5.3R, R Foundation for Statistical Computing, Vienna, Austria, https://www.R-project.org/.

Results

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

In total, 2,771 patients were included (n=1682 healthy volunteers, n=305 subjects with cardiovascular risk factors, and n=784 with cardiovascular disease). Baseline characteristics are presented in Table 1, and average values for the ultimately included ECG measures are presented in Table 2. The ECG measures included in the final prediction models and the intercept and coefficients for the regression equations are also presented in Table 3 for males and Table 4 for females. Agreement between the 10-second Heart Age and the 5-minute Heart Age was excellent $(R^2=0.94, p<0.001, mean\pm SD bias 0.0\pm 5.2 years)$, Figure 1. Agreement was strong for both males and females ($R^2=0.91$, p<0.001, and $R^2=0.92$, p<0.001 respectively). In healthy subjects, on average, the Heart Age and chronological age were no different (0.0±5.7 years), i.e. the Heart Age Gap was zero. In subjects with cardiovascular risk factors, the Heart Age Gap was larger (7.4±7.3 years, p<0.001). Patients with cardiovascular disease showed the largest Heart Age Gap (14.3±9.2 years, p<0.001 vs. subjects at cardiovascular risk), Figure 2. This was evident both for females (Heart Age Gap: healthy subjects: 0.4±5.8 years; cardiovascular risk: 7.8±8.0 years; cardiovascular disease: 14.8±9.0 years, p<0.001) and for males (Heart Age Gap: healthy subjects: -0.3±5.6 years; cardiovascular risk: 7.1±6.6 years; cardiovascular disease: 14.0±9.3 years, p<0.001). A similar pattern was observed for younger (age<60 years) individuals (n=2,142; Heart Age Gap: healthy subjects: 0.1±5.7 years; cardiovascular risk: 7.8±6.4 years; cardiovascular disease: 15.4±9.8 years, p<0.001) and for older individuals (n=629; Heart Age Gap: healthy subjects: -1.7±6.8 years; cardiovascular risk: 7.8±6.4 years; cardiovascular disease: 15.4±9.8 years).

Discussion

We show that Heart Age can be estimated from standard-fidelity, conventional 10-second ECG recordings without requiring more specialised, higher-fidelity, 5-minute long recordings.

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Consequently, ECG-based Heart Age as estimated using Bayesian techniques can now be more readily implemented in clinical practice. ECG-based estimation of Heart Age, as a marker of increased cardiovascular risk, has the advantage of being easily understood by the patient. It might also provide strong incentives for lifestyle changes or compliance to medication, similar to the reporting of "lung age" in the context of smoking cessation¹⁴. For example, in an asymptomatic patient with newly diagnosed hypertension, a value of 160/85 mm Hg may be difficult for the patient to understand in relation to future cardiovascular risk, and the communication of that risk may be difficult for the physician to translate. Instead, if this patient had a chronological age of 50 years but his Heart Age was 10 years higher, it may be more intuitive for the patient to understand that actions are needed. Additionally, an elevated blood pressure is merely a risk factor, and we do not know if the individual patient will suffer from the condition associated with the risk or not. By comparison, changes in the pattern of the ECG and advanced ECG often reflect cardiovascular end-organ changes, some potentially reversible, moving one step beyond the reporting of traditional risk factors. In addition, we found Heart Age to be similar to chronological age in healthy individuals, while the Heart Age Gap was increasingly larger with increasing cardiovascular disease status. This suggests that Heart Age might also provide useful information for cardiovascular risk prediction, although validation in other datasets is necessary. Moreover, more tailored ECG approaches directly geared toward predicting outcomes, rather than indirectly geared toward predicting outcomes through a Heart Age per se, would also likely outperform strictly Heart Age-based attempts at risk stratification. In the dataset used, healthy subjects were younger than subjects with cardiovascular risk factors or disease, and there was also a male preponderance in all three groups. The Heart Age

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

Gap showed a similar pattern in both males and females, and in both younger (<60 years) and older subjects. Estimation of both the 5-minute and 10-second Heart Age currently requires sinus rhythm, since P-wave duration is included in the related calculation. Thus, the assignment of a Heart Age to patients in atrial fibrillation is currently precluded. However, the risk associated with atrial fibrillation is well-established, and patients are often symptomatic. Consequently, the use of Heart Age to incrementally incentivise lifestyle interventions or improve compliance to medications may not be as necessary. Nonetheless, future studies to derive similar methods in patients with atrial fibrillation may also be of value. Explainability and transparency of variables that contribute to ECG Heart Age It is important to note that the patient's chronological age was purposely included in the estimation of Heart Age, just as in the original (5-min ECG) Bayesian model. The original model was not developed to predict a patient's actual chronological age, arguably a task of negligible clinical importance. Rather, the model was developed to estimate the "age" of the heart, and specifically how much that estimate differed from chronological age – quantified as the Heart Age Gap. A Bayesian statistical approach is predicated on knowing the patient's chronological age, with Heart Age being an adjustment of the chronological age based on electrocardiographic characteristics and sex. For an estimation of Heart Age to be accurate in predicting a Heart Age that is similar to the chronological age when the heart is healthy, and increased when the heart is diseased, it is desirable that the included ECG measures change with age, and that the change is augmented with increasing cardiovascular risk or disease severity. The two ECG measures that had the strongest influence (highest t ratio) on the model were Pwave duration and spatial QT duration. This is not surprising, given that P-wave duration increases with age³⁰, and increased P-wave duration can also be seen in advanced

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

cardiovascular pathologies, e.g. heart failure and cardiac amyloidosis³¹. Similarly, QT duration increases with age³². Further, QT prolongation is associated with increased of cardiovascular risk, even beyond the rare long QT syndromes³³, and with incrementally increased risk in advanced ages³⁴. These general characteristics are also true for increased heart rate and for leftward shifting of the frontal plane QRS axis 35-38. The other measures included in the score track changes in the vectorcardiographic QRS and T, and in T-wave complexity by singular value decomposition. Such changes are also known to occur in conditions associated with increased cardiovascular risk, such as hypertension and diabetes³⁹, and in established cardiovascular disease, in which they often provide strong diagnostic and prognostic information^{22-25,27-29}. Notably, these changes are not easily detectable by visual interpretation of a standard 12-lead ECG. How these ECG measures can affect the Heart Age is exemplified in Figure 3. Taken together, the described ECG measures that contribute in a multivariable fashion to the Heart Age all have physiologically reasonable associations with age and disease in a way that is transparent to the assessing clinician, thus providing important explainability to the model. Differences compared to Bayesian 5-minute ECG Heart Age The original, Bayesian 5-minuteECG Heart Age requires information from measures of beatto-beat heart rate and QT variability, and of the root-mean square voltage or other aspects of high-frequency (high fidelity) components of the QRS complex 40-42. However, 10-seconddurationrecordings of standard fidelity do not allow for such measures, and therefore they were not included in the 10-second ECG Heart Age. However, unlike the original Bayesian 5minute ECG Heart Age, the 10-second ECG Heart Age should be derivable from any standard 12-lead ECG machine, as long as it is sufficiently equipped with software that can quantify the included measures and calculate the 10-second ECG Heart Age. The presented 10-second

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

ECG Heart Age might therefore be anticipated to contribute to more widespread clinical penetration and use. Comparison with other Heart (or Vascular) Ages Different means of expressing a heart or vascular age have recently been published¹³, including the use of information in the 10-second 12-lead ECG to estimate ECG Heart Age based on artificial intelligence (AI)^{7,8,10}. For example, Attia, et al, showed that by using a deep neural network (DNN) AI technique, a patient's chronological age could be predicted, and that if the difference between the predicted and actual age was small, prognosis was good ⁸. When Heart Age by Attia et al's technique was notably older than the chronological age, the risk of future death was increased⁷. Such results at least superficially correspond to the findings in our study that the Heart Age Gap increased with increasing burden of cardiovascular risk. Another AI method similar to that of Attia et al also more recently reported similarly encouraging results¹⁰. Although the results of such AI studies are promising, DNN-based AI techniques are nonetheless inherently problematic in several respects, especially in relation to their lack of transparency and explainability, i.e., the 'black box' of AI^{43,44}. Without the ability to know the exact features of the 12-lead ECG that are most important in a given DNN model's output, both interpretability and ethical accountability are compromised⁴⁵. Moreover, it is effectively impossible for a clinician to identify, when critically evaluating the diagnostic output of a DNN-based AI model, the contribution to the result from methodological artifact or bias merely related to noise or to differing technical specifications between different ECG machines⁴⁶. Or the extent to which unanticipated results might merely relate to excess dependency on the particular characteristics of a given DNN AI model's training set⁴⁷. In

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

addition, a major flaw in all DNN-based AI ECG age models of which we are aware is that their age predictions were made using training datasets that also included individuals with both cardiovascular risk factors and established disease^{8,10}. For ECG Heart Age to be used as a marker of potentially reversible cardiovascular disease and risk, it is imperative that ECG Heart Age agrees with chronological age in healthy populations, since it is the deviations from the line of identity in this relationship that form the basis for disease-related assessment and risk. Hence, we believe that the pursuit of an ECG Heart Age developed from heart-healthy subjects of varying ages, but without a black-box DNN or related AI methodology is valuable, and that the present results provide sufficient confirmation of accuracy to encourage further development. Moreover, that the use of more transparent regression models will also increase the ability of clinicians to better understand the origin of any unexpected result, and to thereafter relay it to the patient with a more convincing sense of trust and accountability⁴⁵. Finally, Heart Age can also now be retrospectively determined for clinical purposes or for retrospective scientific studies whenever raw digital data of acceptable quality are available from stored, standard 10-sec ECG recordings. Limitations The dataset was not strictly divided into a training and test set. However, the fact that the selected ECG measures were derived only in the Healthy group, then applied forward to the other groups wherein the Heart Age Gap was incrementally larger with increasing cardiovascular risk and overt disease, does serve as a form of clinical validation. The prognostic value of the Heart Age Gap was not investigated and requires further evaluation in future studies. The use of three different levels of cardiovascular risk or disease status

335

336

337

338

339

340

341

342

343

344

345

346

347

348

(healthy, cardiovascular risk without established disease, and established cardiovascular disease) might also be construed as somewhat arbitrary, although they do constitute a logical grouping with incrementally increasing risk from one group to the next. Future studies are nonetheless also required to validate any association between Heart Age and outcomes associated with different cardiovascular pathologies. Finally, although Heart Age was highly accurate, its precision could not be reliably defined in this study. These aspects therefore need to be addressed in future studies. Conclusion We show that Heart Age can be accurately, transparently, and explainably estimated from a standard 10-second, resting 12-lead ECG utilizing multiple, discrete conventional and advanced ECG measures. The Heart Age Gap increases with increasing cardiovascular risk and disease. However, further prospective evaluation in future studies is also required.

References 349 350 1 Bergström, G. et al. Prevalence of subclinical coronary artery atherosclerosis in the 351 general population. Circulation 144, 916-929, doi:10.1161/circulationaha.121.055340 352 (2021).2 353 Townsend, N. et al. Cardiovascular disease in Europe: epidemiological update 2016. 354 Eur Heart J 37, 3232-3245, doi:10.1093/eurheartj/ehw334 (2016). 355 3 Badimon, L. & Vilahur, G. Thrombosis formation on atherosclerotic lesions and 356 plaque rupture. J Intern Med 276, 618-632, doi:10.1111/joim.12296 (2014). 357 4 Andersson, C. & Vasan, R. S. Epidemiology of cardiovascular disease in young 358 individuals. Nat Rev Cardiol 15, 230-240, doi:10.1038/nrcardio.2017.154 (2018). 359 5 Elliot, C. A. & Hamlin, M. J. Combined diet and physical activity is better than diet or 360 physical activity alone at improving health outcomes for patients in New Zealand's 361 primary care intervention. BMC Public Health 18, 230, doi:10.1186/s12889-018-5152-z (2018). 362 363 6 Lim, S. S. et al. A comparative risk assessment of burden of disease and injury 364 attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a 365 systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224-366 2260, doi:10.1016/s0140-6736(12)61766-8 (2012). 367 7 Ladejobi, A. O. et al. The 12-lead electrocardiogram as a biomarker of biological age. 368 Eur Heart J - Dig Health 2, 379-389, doi:10.1093/ehjdh/ztab043 (2021). 8 369 Attia, Z. I. et al. Age and Sex Estimation Using Artificial Intelligence From Standard 370 12-Lead ECGs. Circulation. Arrhythmia and electrophysiology 12, e007284, 371 doi:10.1161/circep.119.007284 (2019).

372	9	Ball, R. L., Feiveson, A. H., Schlegel, T. T., Starc, V. & Dabney, A. R. Predicting
373		"heart age" using electrocardiography. J Pers Med 4, 65-78, doi:10.3390/jpm4010065
374		(2014).
375	10	Lima, E. M. et al. Deep neural network-estimated electrocardiographic age as a
376		mortality predictor. <i>Nature communications</i> 12 , 5117, doi:10.1038/s41467-021-
377		25351-7 (2021).
378	11	Lopez-Gonzalez, A. A. et al. Effectiveness of the Heart Age tool for improving
379		modifiable cardiovascular risk factors in a Southern European population: a
380		randomized trial. Eur J Prev Cardiol 22, 389-396, doi:10.1177/2047487313518479
381		(2015).
382	12	Soureti, A., Hurling, R., Murray, P., van Mechelen, W. & Cobain, M. Evaluation of a
383		cardiovascular disease risk assessment tool for the promotion of healthier lifestyles.
384		Eur J Cardiovasc Prev Rehab 17, 519-523, doi:10.1097/HJR.0b013e328337ccd3
385		(2010).
386	13	Groenewegen, K. A. et al. Vascular age to determine cardiovascular disease risk: A
387		systematic review of its concepts, definitions, and clinical applications. Eur J Prev
388		Cardiol 23, 264-274, doi:10.1177/2047487314566999 (2016).
389	14	Parkes, G., Greenhalgh, T., Griffin, M. & Dent, R. Effect on smoking quit rate of
390		telling patients their lung age: the Step2quit randomised controlled trial. BMJ 336,
391		598-600, doi:10.1136/bmj.39503.582396.25 (2008).
392	15	Maanja, M. et al. The electrical determinants of increased wall thickness and mass in
393		left ventricular hypertrophy. J Electrocardiol 58, 80-86,
394		doi:10.1016/j.jelectrocard.2019.09.024 (2020).
395	16	Schlegel, T. T. et al. Accuracy of advanced versus strictly conventional 12-lead ECG
396		for detection and screening of coronary artery disease, left ventricular hypertrophy and

397		left ventricular systolic dysfunction. BMC cardiovasc disord 10, 28,
398		doi:10.1186/1471-2261-10-28 (2010).
399	17	Johnson, K. et al. Advanced Electrocardiography Identifies Left Ventricular Systolic
400		Dysfunction in Non-Ischemic Cardiomyopathy and Tracks Serial Change over Time. J
401		Cardiovasc Dev Dis 2, 93-107, doi:10.3390/jcdd2020093 (2015).
402	18	Vrtovec, B., Sinkovec, M., Starc, V., Radovancevic, B. & Schlegel, T. T. Coronary
403		artery disease alters ventricular repolarization dynamics in type 2 diabetes. Pacing
404		Clin Electrophysiol 28 Suppl 1 , S178-181, doi:10.1111/j.1540-8159.2005.00076.x
405		(2005).
406	19	Persson, E., Carlsson, M., Palmer, J., Pahlm, O. & Arheden, H. Evaluation of left
407		ventricular volumes and ejection fraction by automated gated myocardial SPECT
408		versus cardiovascular magnetic resonance. Clin Physiol Funct Imaging 25, 135-141,
409		doi:10.1111/j.1475-097X.2005.00599.x (2005).
410	20	Trägårdh, E. et al. High-frequency electrocardiogram analysis in the ability to predict
411		reversible perfusion defects during adenosine myocardial perfusion imaging. J
412		Electrocardiol 40, 510-514, doi:10.1016/j.jelectrocard.2007.03.242 (2007).
413	21	Lang, R. M. et al. Recommendations for cardiac chamber quantification by
414		echocardiography in adults: an update from the American Society of
415		Echocardiography and the European Association of Cardiovascular Imaging. Eur
416		Heart J Cardiovasc Imaging 16, 233-270, doi:10.1093/ehjci/jev014 (2015).
417	22	Yamazaki, T., Froelicher, V. F., Myers, J., Chun, S. & Wang, P. Spatial QRS-T angle
418		predicts cardiac death in a clinical population. Heart rhythm 2, 73-78,
419		doi:10.1016/j.hrthm.2004.10.040 (2005).

420	23	Fayn, J., Rubel, P., Pahlm, O. & Wagner, G. S. Improvement of the detection of
421		myocardial ischemia thanks to information technologies. <i>Int J Cardiol.</i> 120 , 172-180,
422		doi:10.1016/j.ijcard.2006.09.025 (2006).
423	24	Kardys, I. et al. Spatial QRS-T angle predicts cardiac death in a general population.
424		European heart journal 24 , 1357-1364, doi:10.1016/S0195-668X(03)00203-3 (2003).
425	25	Horinaka, S. et al. Ventricular gradient variability. New ECG method for detection of
426		ischemic heart disease. J Electrocardiol 28, 177-183, doi:10.1016/S0022-
427		0736(05)80255-9 (1995).
428	26	Kors, J. A., van Herpen, G., Sittig, A. C. & van Bemmel, J. H. Reconstruction of the
429		Frank vectorcardiogram from standard electrocardiographic leads: diagnostic
430		comparison of different methods. Eur Heart J 11, 1083-1092 (1990).
431	27	Zabel, M. et al. Analysis of T-wave morphology from the 12-lead electrocardiogram
432		for prediction of long-term prognosis in male US veterans. Circulation (New York,
433		N.Y.) 105 , 1066-1070, doi:10.1161/hc0902.104598 (2002).
434	28	Okin, P. M. et al. Repolarization Abnormality for Prediction of All-Cause and
435		Cardiovascular Mortality in American Indians: The Strong Heart Study. J $Cardiovasc$
436		Electrophysiol 16, 945-951, doi:10.1111/j.1540-8167.2005.40808.x (2005).
437	29	Priori, S. G. et al. Evaluation of the spatial aspects of T-wave complexity in the long-
438		QT syndrome. Circulation (New York, N.Y.) 96, 3006-3012,
439		doi:10.1161/01.CIR.96.9.3006 (1997).
440	30	Chhabra, L., Devadoss, R., Chaubey, V. K. & Spodick, D. H. Interatrial Block in the
441		Modern Era. Curr Cardiol Rev 10, 181-189,
442		doi:10.2174/1573403X10666140514101748 (2014).

443	31	Lindow, T. & Lindqvist, P. The prevalence of advanced interatrial block and its
444		relationship to left atrial function in patients with transthyretin cardiac amyloidosis. J
445		Clin Med 10, doi:10.3390/jcm10132764 (2021).
446	32	Rautaharju, P. M., Mason, J. W. & Akiyama, T. New age- and sex-specific criteria for
447		QT prolongation based on rate correction formulas that minimize bias at the upper
448		normal limits. <i>Int J Cardiol</i> 174 , 535-540, doi:10.1016/j.ijcard.2014.04.133 (2014).
449	33	Shah, S. R., Park, K. & Alweis, R. Long QT Syndrome: A comprehensive review of
450		the literature and current evidence. Curr Prob Cardiol 44, 92-106,
451		doi:10.1016/j.cpcardiol.2018.04.002 (2019).
452	34	Nielsen, J. B. et al. Risk prediction of cardiovascular death based on the QTc interval:
453		evaluating age and gender differences in a large primary care population. Eur Heart J
454		35, 1335-1344, doi:10.1093/eurheartj/ehu081 (2014).
455	35	Goorakani, Y. et al. Correlation of resting heart rate with anthropometric factors and
456		serum biomarkers in a population-based study: Fasa PERSIAN cohort study. BMC
457		cardiovasc disord 20 , 319-319, doi:10.1186/s12872-020-01594-y (2020).
458	36	Ogliari, G. et al. Resting heart rate, heart rate variability and functional decline in old
459		age. Can Med Assoc J 187, E442-e449, doi:10.1503/cmaj.150462 (2015).
460	37	Morcet, J. F., Safar, M., Thomas, F., Guize, L. & Benetos, A. Associations between
461		heart rate and other risk factors in a large French population. J Hypertens 17, 1671-
462		1676, doi:10.1097/00004872-199917120-00003 (1999).
463	38	Evans, J. G., Prior, I. A. & Tunbridge, W. M. Age-associated change in QRS axis:
464		intrinsic or extrinsic ageing? <i>Gerontology</i> 28 , 132-137, doi:10.1159/000212523
465		(1982).

466	39	Bergfeldt, L. et al. Spatial peak and mean QRS-T angles: A comparison of similar but
467		different emerging risk factors for cardiac death. J Electrocardiol 61, 112-120,
468		doi:10.1016/j.jelectrocard.2020.05.013 (2020).
469	40	Ringborn, M. M. D. et al. Comparison of high-frequency QRS components and ST-
470		segment elevation to detect and quantify acute myocardial ischemia. J Electrocardiol
471		43 , 113-120, doi:10.1016/j.jelectrocard.2009.11.009 (2010).
472	41	Trägårdh, E., Pahlm, O., Wagner, G. S. & Pettersson, J. Reduced high-frequency QRS
473		components in patients with ischemic heart disease compared to normal subjects. J
474		Electrocardiol 37, 157-162, doi:10.1016/j.jelectrocard.2004.02.004 (2004).
475	42	Schlegel, T. T. et al. Real-Time 12-Lead High-Frequency QRS Electrocardiography
476		for Enhanced Detection of Myocardial Ischemia and Coronary Artery Disease. Mayo
477		Clin Proc 79, 339-350, doi:10.4065/79.3.339 (2004).
478	43	Gladding, P. A., Hewitt, W. & Schlegel, T. T. Going deep with ecg and aortic
479		stenosis: Touchdown or incomplete pass? J Am Heart Assoc 9, e016193-e016193,
480		doi:10.1161/JAHA.120.016193 (2020).
481	44	The Lancet Respiratory Medicine. Opening the black box of machine learning. Lancet
482		Resp Med 6, 801-801, doi:10.1016/S2213-2600(18)30425-9 (2018).
483	45	Yoon, C. H., Torrance, R. & Scheinerman, N. Machine learning in medicine: should
484		the pursuit of enhanced interpretability be abandoned? J Med Ethics,
485		doi:10.1136/medethics-2020-107102 (2021).
486	46	Brisk, R. et al. The effect of confounding data features on a deep learning algorithm to
487		predict complete coronary occlusion in a retrospective observational setting. Eur
488		Heart J - Dig Health 2, 127-134, doi:10.1093/ehjdh/ztab002 (2021).

Siontis, K. C. et al. Use of Artificial Intelligence Tools Across Different Clinical Settings: A Cautionary Tale. Circulation. Cardiovasc Qual Outcomes 14, e008153, doi:10.1161/circoutcomes.121.008153 (2021).

Table 1. Baseline characteristics

	All (n=2,771)	Healthy (n=1,682)	Subjects at CV risk (n=305)	Patients with CV disease (n=784)	p
Age, years	46.2 [16.0]	38.6 13.0]	54.8 [11.2]	59.0 [13.2]	< 0.001
Male sex, n (%)	1645 [59.4]	999 [59.4]	163 [53.4]	483 [61.6]	0.048
5-minute ECG Heart Age, years	51.1 [21.7]	38.3 14.1]	61.9 [13.2]	74.2 [15.6]	<0.001
CAD, n (%)	421 [15.2]	-	-	421 [53.7]	-
ICM, n (%)	120 [4.3]	-	-	120 [15.3]	-
HCM, n (%)	92 [3.3]	-	-	92 [11.7]	-
LVH, n (%)	96 [3.5]	-	-	96 [12.2]	-
NICM, n (%)	53 [1.9]	-	-	53 [6.8]	-

Age and 5-minute ECG Heart Age are presented as mean (standard deviation).

Abbreviations: CAD: coronary artery disease; ICM: ischemic cardiomyopathy; HCM:

hypertrophic cardiomyopathy; LVH: left ventricular hypertrophy; NICM: non-ischemic cardiomyopathy

Table 2. ECG measures in all patients, stratified by health, cardiovascular risk or cardiovascular disease

Measure	All (n=2,771)	Healthy (n=1,682)	Subjects at CV risk (n=305)	Patients with CV disease (n=784)	p
P-wave duration, ms	105 [15]	99 [13]	109 [14]	114 [15]	< 0.001
Spatial QT interval, ms	432 [38]	428 [32]	425 [37]	445 [46]	< 0.001
Heart rate, min ⁻¹	65 [11]	63 [10]	70 [11]	67 [13]	< 0.001
QRS max amplitude in VCG lead Y, µV	988 [454]	1144 [392]	828 [363]	717 [462]	< 0.001
Frontal plane QRS axis, radians	0.64 [0.44]	0.82 [0.23]	0.54 [0.44]	0.29 [0.54]	<0.001
T-wave complexity, Ln Σ (EV3:8) / (EV1–EV2), unitless	-2.9 [0.7]	-3.2 [0.5]	-2.9 [0.6]	-2.3 [0.9]	<0.001
Spatial ventricular gradient minus Spatial mean QRS, mV*s	0.044 [0.030]	0.059 [0.021]	0.038 [0.017]	0.016 [0.028]	<0.001
QRS RMS in VCG vector magnitude lead, mV	0.52 [0.15]	0.53 [0.13]	0.47 [0.11]	0.50 [0.21]	<0.001
QRS average spatial velocity in VCG vector magnitude lead, mV/s	45 [12]	46 [10]	43 [16]	43 [10]	<0.001
Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG, %	11 [15]	6 [8]	11 [15]	17 [22]	<0.001

All values are presented as mean (standard deviation).

Abbreviations: CV: cardiovascular; Ln: Natural logarithm; EV: Eigenvalues;

VCG: vectocardiographic; RMS: root mean square

Table 3. Measures included in the 10-second ECG Heart Age for male subjects.

Measure	Estimate	Standard error	t ratio
(Intercept)	-60.575	2.353	-25.73
Age, years	0.820	0.007	113.73
P-wave duration, ms	0.288	0.007	39.99
Spatial QT interval, ms	0.081	0.004	22.86
Heart rate, min ⁻¹	0.242	0.012	20.02
QRS max amplitude in VCG lead Y, μV	-0.007	0.000	-18.20
Frontal plane QRS axis, radians	-5.834	0.395	-14.75
T-wave complexity, Ln Σ (EV3:8) / (EV1–EV2), unitless	2.152	0.164	13.12
Spatial ventricular gradient minus Spatial mean QRS, $mV*s$	-55.841	4.464	-12.51
Male sex (value=1)	1.996	0.215	9.27
QRS RMS in VCG vector magnitude lead, mV	10.315	1.612	6.40
QRS average spatial velocity in VCG vector magnitude lead, mV/s	0.106	0.017	6.30
Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG, %	0.033	0.009	3.55

Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square

Table 4. Measures included in the 10-second ECG Heart Age for female subjects.

Measure	Estimate	Standard error	t ratio
(Intercept)	-70.477	2.662	-26.47
Age, years	0.850	0.008	104.26
P-wave duration, ms	0.331	0.008	40.73
Spatial QT interval, ms	0.095	0.004	23.58
Heart rate, min ⁻¹	0.281	0.014	20.57
QRS max amplitude in VCG lead Y, μV	-0.009	0.000	-18.54
Frontal plane QRS axis, radians	-6.354	0.447	-14.21
Spatial ventricular gradient minus Spatial mean QRS, $mV*_S$	-67.642	5.049	-13.40
T-wave complexity, Ln Σ (EV3:8) / (EV1–EV2), unitless	2.359	0.185	12.72
QRS RMS in VCG vector magnitude lead,mV	11.701	1.822	6.42
QRS average spatial velocity in VCG vector magnitude lead, $\ensuremath{mV/s}$	0.116	0.019	6.10
Portion of QRS loop in posterior superior quadrant of left sagittal plane by VCG, %	0.034	0.010	3.22

Abbreviations: Ln: Natural logarithm; EV: Eigenvalues; VCG: vectocardiographic; RMS: root mean square

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546


547


548

Figure 1. Left panel: Scatter plot showing the relation between the 10-second ECG Heart Age and the 5-minute ECG Heart Age in all participants. The R² value was 0.94 (p<0.001). Right panel: Bland-Altman plot showing the difference between the 10-second and 5-minute ECG Heart Age in relation to the mean of both ECG Heart Ages. The agreement between methods is strong, with minimal deviation from the identity line (dashed) or bias $(0.0\pm5.2 \text{ years})$. Figure 2. Panel A: The difference (the Heart Age Gap) between the 10-second ECG Heart Age and chronological age in healthy subjects (left, dark green), subjects at cardiovascular (CV) risk (middle, light blue), and patients with CV disease (right, yellow). On average, there is no difference between Heart Age and chronological age in healthy subjects. Heart Age Gap is higher in subjects at CV risk, and highest for those with overt CV disease. Panel B: Scatter plots showing the relationship between the 10-second ECG Heart Age and chronological age in healthy subjects (left, dark green), subjects at CV risk (middle, light blue), and patients with CV disease (right, yellow). The dashed diagonal line is the identity line, i.e. indicating no difference between Heart Age and chronological age. **Figure 3.** Example of the transparency and explainability of the Heart Age from two subjects with equal chronological age but different Heart Ages, illustrated by a commensurately aged female heart, but a disproportionately aged male heart. The ECG measures for each of the two patients are shown in the table in the middle of the figure, presented in the order of the relative strength (strongest first, based on t ratio [not shown]) of contribution to the Heart Age. Notably, P-wave duration is markedly different between these two patients, and heart rate is higher for the male than the female, helping drive the Heart Age higher in the male. The R-wave amplitude in lead Y is also much larger in the female, and the difference between

the spatial ventricular gradient and the spatial mean QRS in the female is also larger, likely due to preserved T-wave amplitudes, contributing to her relatively younger Heart Age.

Furthermore, possibly due to ischemic myocardial injuries, T-wave complexity is increased in the male, suggesting that increased myocardial repolarisation heterogeneity also contributes to driving Heart Age higher in the male, in spite of his shorter QT interval.









60-year old, healthy female without cardiovascular risk factors or medications

90 ms

55/min

835 µV

0.58 radians

0.038 mV*s

-1.92

0.43 mV

39.1 mV/s

12.7%

60-year old male with heart failure following myocardial infarction

ECG measures

P-wave duration	
Spotial OT intorval	

447 ms

Spatial QT interval Heart rate

QRS max amplitude in VCG lead Y Frontal plane QRS axis

Spatial ventricular gradient - spatial mean QRS T-wave complexity, Ln QRS RMS in VCG vector magnitude lead

QRS average spatial velocity in vector magnitude lead Portion of QRS loop in posterior superior quadrant of left sagital plane by VCG



148 ms

380 ms 70/min 299 µV

0.64 radians 0.003 mV*s 1.21

23.5 mV/s 25.2% **ECG HEART AGE** 79 years

0.31 mV

